PMA device
Biolon 1% Sodium Hyaluronate for Ophthalmic Surgery
Altacor , Ltd. · Aid, Surgical, Viscoelastic (LZP, Class III) · First FDA decision Mar 23, 2001, newest Sep 15, 2005Cataract
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
97
Naming "Biolon 1 Sodium"
MAUDE reports
0
Brand "Biolon 1 Sodium", since 2015
PubMed studies
0
Mentioning "Biolon 1 Sodium"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Biolon 1% Sodium Hyaluronate for Ophthalmic Surgery
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- BIOLON 1% SODIUM HYALURONATE FOR OPHTHALMIC SURGERYPMA supplement
P960011-S010 · Decided Sep 15, 2005 · 127 days after receipt · Normal 180 Day Track No User Fee
Device type: AID, SURGICAL, VISCOELASTIC (LZP) · Ophthalmology
- BIOLON 1% SODIUM HYALURONATE FOR OPHTHALMIC SURGERYPMA supplement
P960011-S004 · Decided Mar 23, 2001 · 346 days after receipt · Normal 180 Day Track
Device type: AID, SURGICAL, VISCOELASTIC (LZP) · Ophthalmology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Biolon 1 Sodium", any status and sponsor, newest update first.
- Halova Vaginal Ovules Versus Vaginal Estriol for Genitourinary Symptoms in Postmenopausal WomenCompleted
Perfect Care DistributionNot on our public-company list
NCT07932990 · 252 participants · Start Mar 7, 2025 · Primary completion Apr 22, 2026
Device: Halova vaginal ovules · For: Genitourinary Syndrome of Menopause (GSM); Vaginal Dryness; Vulvo Vaginal Atrophy (VVA)
Sites: Arad, Romania
- Comparing Injection Treatments for Tennis ElbowPivotal-lookingRecruiting
Wrightington, Wigan and Leigh NHS Foundation TrustAcademic, hospital or other
NCT03984955 · 123 participants (planned) · Start Apr 18, 2018 · Primary completion Feb 6, 2028
Device: Sodium hyaluronate with mannitol (Ostenil Tendon); Platelet-Rich Plasma Injection · For: Tennis Elbow; Lateral Epicondylitis; Elbows Tendonitis
Sites: Wigan, United Kingdom
- Halova Vaginal Ovules Versus Placebo for Genitourinary Symptoms in Premenopausal WomenPivotal-lookingCompleted
Perfect Care DistributionNot on our public-company list
NCT07927088 · 150 participants · Start Feb 22, 2025 · Primary completion Mar 20, 2026
Device: Halova vaginal ovules; Placebo vaginal ovules · For: Vaginal Dryness; Genitourinary Symptoms
Sites: Arad, Romania
94 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Biolon 1 Sodium", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code LZP
1,607 reports: 550 malfunction, 1,056 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0606-2011 · Started Oct 4, 2010 · Posted by FDA Dec 16, 2010
Reason given: Finger flange on the BD 1% OVD syringe can disengage during cataract surgery and and may lead to injury.
Cause as FDA categorized it: Component design/selection · Device type: Aid, Surgical, Viscoelastic (LZP)
Published research
The most relevant PubMed records for "Biolon 1 Sodium"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code LZP.
- PROVISC Ophthalmic Viscosurgical DeviceAlcon Research, Ltd. · PMA 2026
- Sodium Hyaluronate Ophthalmic Viscoelastic Devices (OVD)Johnson & Johnson Surgical Vision, Inc. · PMA 2024
- Amvisc & Amvisc Plus OvdBausch & Lomb, Inc. · PMA 2017
- Staarvisc II & Shellgel Sodium HyauronateAnika Therapeutics, Inc. · PMA 2012
- VISCOAT Ophthalmic Viscosurgical DeviceAlcon Laboratories · PMA 2026
- DISCOVISC Ophthalmic Viscosurgical DeviceAlcon Laboratories · PMA 2021
- Cellugel(R) Ophthalmic Viscosurgical DeviceAlcon Laboratories · PMA 2016
- Ocucoat (2% Hydroxpropylmethylcellulose Solution)Bausch & Lomb, Inc. · PMA 2012
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.